menu

NEWS

Streck establishes partnership with Ceres Nanosciences to distribute COVID-19 wastewater surveillance solution

La Vista, NE – January 10, 2022 Streck today announced a partnership with Ceres Nanosciences to distribute Nanotrap® Magnetic Virus Particles that provide rapid viral concentration directly from raw sewage. This product dramatically reduces the time and effort required to test wastewater samples for COVID-19 surveillance. Wastewater surveillance can act as an early-warning system for COVID-19 “hotspots” within a community. The Ceres Nanotrap Magnetic Virus Particles facilitate a streamlined workflow, improved sensitivity, and reduced time to results. Nanotrap Magnetic Virus Particles are For Research Use Only. Not for use in diagnostic procedures. Traditional methods for concentration of virus from wastewater are...

READ MORE
Ceres Nanosciences Establishes Nine Wastewater-based COVID-19 Surveillance Centers of Excellence Under NIH RADx Initiative

MANASSAS, Virginia – November 9, 2021 Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve life science research and diagnostic testing, is announcing the establishment of nine new wastewater-based epidemiology centers of excellence, as part of the April 2021 $8.2 million award from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative. Wastewater-based epidemiology can help communities monitor infection dynamics for SARS-CoV-2 and can serve as an early-warning system for the virus in a population, but widespread implementation has been stymied by lack of robust, high-throughput viral concentration methods.​ Ceres’ Nanotrap® Magnetic Virus Particles address...

READ MORE
Genetika+ CEO Talia Cohen Solal Brings Precision Medicine to Brain Health

BioSpace // Published October 21, 2021 | By Gail Dutton Genetika+ CEO and Co-founder Talia Cohen Solal/Courtesy Genetika+.  Depression, historically, has been treated by trial and error until a therapy with a positive and stable outcome can be identified. Genetika+ is changing that with precision, personalized testing that enables the right antidepressant to be selected for patients the first time. “We’re developing a blood test to match therapies to patients,” Talia Cohen Solal, Ph.D., CEO and co-founder of Genetika+, told BioSpace. The test doesn’t directly assay the blood, though. Instead, “We take the blood cells and use stem cell technology to cause...

READ MORE
Genetika+ – A Pioneer in Personalized Medicine for Psychiatry – Raises $10 Million in an Oversubscribed Series A

JERUSALEM AND BOSTON (PRWEB) SEPTEMBER 30, 2021 New investment underscores the company’s promise to transform precision medicine and mental health Genetika+, bringing the first personalized medicine platform for optimizing psychiatric and neurologic patient treatment, announced today that it has closed a $10 million Series A funding round led by GreyBird Ventures, a Boston-based VC focused on precision medicine. Also participating in the round are Meron Capital, Jumpspeed Ventures, Sapir Venture Partners, Howard Morgan Chairman of B Capital Group and Michael Zeisser of FMZ Ventures and former Chairman, Investments at Alibaba Group. Genetika+’s lead solution personalizes antidepressant treatment for each patient. The...

READ MORE
Angstrom Bio Raises $3M in Private Financing

Jun 16, 2021 | staff reporter NEW YORK — Angstrom Bio said on Wednesday that it has secured a $3 million investment that it will use to launch a nanopore sequencing-based test that simultaneously detects SARS-CoV-2 infection and identifies variants of the virus and to develop a multiplexed panel for respiratory pathogens. The investment was led by GreyBird Ventures. In connection with the financing, GreyBird cofounders Scott Gazelle and Tom Miller have joined Angstrom’s board of directors. Angstrom was founded in 2019 to develop antibody therapeutics but pivoted to SARS-CoV-2 diagnostics at the start of the pandemic. The Austin, Texas-based company uses a technology, dubbed...

READ MORE
Germany’s GNA Biosolutions Commercializing Rapid MDx Instrument, SARS-CoV-2 Test

Jan 27, 2021  NEW YORK – With recent regulatory approval in Germany, GNA Biosolutions has begun commercializing a rapid, moderate-throughput, sample-to-answer molecular diagnostics instrument called Octea along with an assay for SARS-CoV-2. The Munich-based firm also is using support from the Innovative Medicines Initiative (IMI) to develop its technology into a disposable molecular diagnostics system, which it expects to be a pioneer in instrument-free home-use molecular testing.    GNA Biosolutions received Emergency Use Authorization from the German Federal Institute for Drugs and Medical Devices for its SARS-CoV-2 test on the Octea instrument late last year. The Octea tests eight samples simultaneously, while...

READ MORE
1 2 3 6
GreyBird Ventures

is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.

MEET THE PEOPLE

For additional information, please contact: greybird@greybirdventures.com

DISCLAIMER